Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

Cancer letters - 1 Jun 2010

Kachnic Lisa A, Li Li, Fournier Loreen, Willers Henning

Abstract excerpt

Genetic or epigenetic inactivation of the pathway formed by the Fanconi Anemia (FA) proteins occurs in several cancer types, including head and neck squamous cell carcinomas (HNSCC), rendering the affected tumors potentially hypersensitive to DNA crosslinking agents. However, the cytotoxicity of other commonly used cancer therapeutics in cells with FA pathway defects remains to be defined. Here, we focused on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Transformed
Share to Cisplatin
Share to Fanconi Anemia Complementation Group A Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fanconi Anemia Complementation Group D2 Protein

Share to Fanconi Anemia Complementation Group Proteins

Share to Head and Neck Neoplasms

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Identifiers

PMID: 20034732
DOI: 10.1016/j.canlet.2009.11.009

Genes

FANCD2
FANCC
FANCA
RAD51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.PMID 20034732Read ↗

Fanconi anemia-isogenic head and neck cancer cell line pairs - a basic and translational science resourceSemantic proximity Read ↗

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.Semantic proximity Read ↗

Fanconi anemia‐isogenic head and neck cancer cell line pairs: A basic and translational science resourceSemantic proximity Read ↗

Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung CancerSemantic proximity Read ↗

Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.Semantic proximity Read ↗

Fanconi Anemia Pathway Deficiency Drives Copy Number Variation in Squamous Cell CarcinomasSemantic proximity Read ↗

Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patientsSemantic proximity Read ↗

The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.Semantic proximity Read ↗

Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and TherapySemantic proximity Read ↗

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer TherapySemantic proximity Read ↗

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.Semantic proximity Read ↗

Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.